The Affiliated Hospital Of Xuzhou Medical University
Clinical trials sponsored by The Affiliated Hospital Of Xuzhou Medical University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on autoimmune diseases Results expected Sep 2026 (estimated)
- New triple attack on advanced cancers enters human testing Results expected Dec 2026 (estimated)
- Experimental CAR-T therapy takes on stubborn muscle weakness Results expected Jun 2027 (estimated)
- New drug cocktail aims to outsmart aggressive blood cancer Results expected Jun 2027 (estimated)
-
New drug cocktail aims to outsmart aggressive blood cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy, with or without a stem cell transplant, can improve outcomes for people newly diagnosed with an aggressive type of non-Hodgkin lymphoma called DLBCL. The study enrolls 30 adults aged…
Phase 2 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on stubborn muscle weakness
Disease control Recruiting nowThis early study is testing a new drug, HN2302 (a type of in vivo CAR-T therapy), in just 6 people with refractory myasthenia gravis — a condition where standard treatments fail. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it helps wi…
Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New triple attack on advanced cancers enters human testing
Disease control Recruiting nowThis early-phase trial tests whether combining an experimental drug (AT1019), targeted radiation (SBRT), and an immunotherapy (PD-1 inhibitor) is safe for people with advanced solid tumors. About 12 participants will receive the combination and be monitored for side effects and t…
Phase 1 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Promising cocktail of drugs takes on rare blood cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of five drugs—tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone—in 40 people newly diagnosed with angioimmunoblastic T-cell lymphoma (AITL), a rare and aggressive blood cancer. The goal is to see if this …
Phase 2 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jun 26, 2026 15:37 UTC
-
Your genes may determine if diabetes drug works
Knowledge-focused Recruiting nowThis study looks at how a person's genes influence their response to GLP-1 RA drugs (like exenatide and liraglutide) for type 2 diabetes. Researchers will analyze blood samples from 300 patients to find genetic markers that predict whether the drug lowers blood sugar and weight. …
Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:20 UTC